COGNITION THERAPEUTICS INC
For the period ended Dec 31, 2023. Filed Mar 26, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 26, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
Rule 10b5-1 Trading Plans
During the three months ended December 31, 2023, the following directors or officers (as defined in Rule 16a-1(f) of the Exchange Act) adopted or terminated a “Rule 10 b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(c) of Regulation S-K:
| Name and Title | Action | Date | Plan | Aggregate Number of securities to be sold | Plan Expiration Date |
|---|---|---|---|---|---|
| Aaron Fletcher, Director(1) | Adoption | December 29, 2023 | Rule 10b5-1 | 2,000,000 | March 28, 2025 |
(1) The plan was adopted by BIOS Equity Partners, LP. BIOS Capital Management, LP is the general partner of BIOS Equity Partners, LP. Bios Advisors GP, LLC, an entity controlled by Dr. Aaron Fletcher, is the general partner of Bios Management. As the manager of Bios Advisors, Dr. Fletcher may be deemed to have shared voting and/or dispositive power with respect to shares directly or indirectly held by the
BIOS Equity Partners LP.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.